Antibiotics susceptibility and genetic characteristics analysis for quinolone resistant Campylobacter jejuni isolated from China
FU Yan-yan1, GU Yi-xin1, SONG Li2, LI Ying3, DUAN Yong-xiang4, LIANG Hao1, ZHANG Mao-jun1
1. State Key of Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; 2. China Institute of Veterinary Drugs Control, Beijing 100081, China; 3. Beijing Shunyi Center for Disease Control and Prevention, Beijing 101300, China; 4. Shenzhen Nanshan Center for Disease Control and Prevention, Shenzhen 518000, China
Abstract：According to CLSI, agar dilution method was used to analyze the minimum inhibitory concentrations (MIC) of the nalidixic acid and ciprofloxacin for the isolates from different sources. Mutations in the quinolone resistant determining region (QRDR) of gyrA and gyrB were examined by DNA sequencing of 102 resistant C. jejuni isolates and 27 sensitive isolates. The results showed that 218 isolates(93.16%) were resistant to nalidixic acid among the entire tested 234 isolates. Among these, the resistant rates of the isolates from chicken feaces, duck feaces, human feaces, food animal and cow feaces were 100.00%, 100.00%, 97.96%, 97.83% and 77.97%, respectively. The 211 isolates(90.17%) were resistant to ciprofloxacin. Among these, the resistant rates of the isolates from chicken feaces, duck feaces, human feaces, food animal and cow feaces were 100.00%, 100.00%, 91.84%, 95.65% and 77.97%, respectively. The differences were both statistically significant. All of the resistant isolates on the QRDR of gyrA had Thr-86-Ile mutation. However, the point substitutions in gyrB gene were synonymous mutations. The results indicated that the C. jejuni isolates in this study showed highly resistant to nalidixic acid and ciprofloxacin. The Thr-86-Ile mutation on the QRDR of gyrA can cause highly resistant to quinolone and fluoroquinolone for C. jejuni.
[1] Huang JL,Xu HY, Bao GY, et al. Epidemiological surveillance of Campylobacter jejuni in chicken, dairy cattle and diarrhea patients[J]. Epidemiol Infect, 2009, 137(8): 1111-1120. [2] Kaakoush NO, Castanorodríguez N, Mitchell HM, et al. Global epidemiology of Campylobacter infection[J]. Clin Microbiol Rev, 2015, 28(3):687-720. [3] Hermans D, Pasmans F, Messens W, et al. Poultry as a host for the zoonotic pathogen Campylobacter jejuni [J]. Vector Borne Zoonotic Dis, 2012, 12(2):89. [4] Coker AO, Isokpehi RD, Thomas BN, et al. Human campylobacteriosis in developing countries1[J]. Emerg Infect Dis, 2002, 8(3):237-44. [5] Allos BM. Campylobacter jejuni infections: update on emerging issues and trends[J]. Clin Infect Dis, 2001, 32(8):1201. [6] Ruizpalacios GM. The health burden of Campylobacter infection and the impact of antimicrobial resistance: playing chicken[J]. Clin Infect Dis, 2007, 44(5):701. [7] Luangtongkum T, Jeon B, Han J, et al. Antibiotic resistance in Campylobacter : emergence, transmission and persistence[J]. Future Microbiol, 2009, 4(2):189-200. [8] CDC. Antibiotic resistance threats in the United States [EB/OL]. (2013-7-14)[2013-4-23]. http://www.cdc.gov/drugresistance/threat-report-2013/. [9] WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics.[EB/OL].[2017-2-27] http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. [10] Pumbwe L, Randall LP, Woodward MJ, et al. Evidence for multiple-antibiotic resistance in Campylobacter jejuni not mediated by CmeB or CmeF[J]. Antimicrob Agents Chemother, 2005, 49(4):1289. [11] Charvalos E, Tselentis Y, Hamzehpour MM, et al. Evidence for efflux pump in multidrug resistant C.jejuni [J]. Antimicrob Agents Chemother, 1995, 39(9):2019-2022. [12] Liu XY, Yu JF, Gu YX, et al. Laboratory detection and surveillance of Campylobacter jejuni infection[J]. Dis Surveill, 2014, 29(5): 354-358. (in Chinese) 刘夏阳, 于俊峰, 顾一心,等. 感染性腹泻患者弯曲菌感染的实验室检测及监测[J].疾病监测, 2014, 29(5):354-358. [13] Hakanen A, Jalava J, Kotilainen P, et al. gyrA polymorphism in Campylobacter jejuni : detection of gyrA mutations in 162 C. jejuni isolates by single-strand conformation polymorphism and DNA sequencing[J]. Antimicrob Agents Chemother, 2002, 46(8): 2644-2647. [14] Gupta A, Nelson JM, Barrett TJ, et al. Antimicrobial resistance among Campylobacter strains, United States, 1997-2001[J]. Emerg Infect Dis, 2004, 10(6): 1102-1109 [15] Thakur S, Zhao S, Mcdermott PF, et al. Antimicrobial resistance, virulence, and genotypic profile comparison of Campylobacter jejuni and Campylobacter coli isolated from humans and retail meats[J]. Foodborne Pathog Dis, 2010, 7(7):835-844. [16] Riley A, Eshaghi A, Olsha R, et al. Antibiotic susceptibility of clinical isolates of Campylobacter jejuni and Campylobacter coli in Ontario, Canada during 2011-2013[J]. Diagn Micr Infec Dis, 2015, 83(3):292-294. [17] Prasad KN, Mathur SK, Dhole TN, et al. Antimicrobial susceptibility and plasmid analysis of Campylobacter jejuni isolated from diarrheal patients and healthy chickens in northern India[J]. J Diarrheal Dis Res, 1994, 12(4):270-3. [18] Jain D, Sinha S, Prasad KN, et al. Campylobacter species and drug resistance in a north Indian rural community[J]. Trans R Soc Trop Med Hyg, 2005, 99(3):207-214. [19] Mukherjee P, Ramamurthy T, Bhattacharya MK, et al. Campylobacter jejuni in hospitalized patients with diarrhea, Kolkata, India[J]. Emerg Infect Dis, 2013, 19(7):1155. [20] Gu YX, He LH, Liu HY, et al. Drug susceptibility of Campylobacter jejuni isolated in China[J]. Dis Surveill, 2013, 28(4): 314-318. (in Chinese) 顾一心, 何利华, 刘红莹,等. 空肠弯曲菌耐药谱特征分析[J].疾病监测, 2013, 28(4):314-318. [21] Zhang AY. Antibiotic susceptibility and genetic characteristics of Campylobacter isolated in China[D]. Beijing: Chinese Center for Disease Control and Prevention, 2015. (in Chinese) 张艾煜. 弯曲菌抗生素敏感性及遗传特征分析[D]. 北京:中国疾病预防控制中心, 2015. [22] Qin SS, Wu CM, Wang Y, et al. Antimicrobial resistance in Campylobacter coli isolated from pigs in two provinces of China[J]. Int J Food Microbiol, 2011, 146(1):94-98. [23] Zhou J, Zhang M, Wanna Y, et al. A seventeen-year observation of the antimicrobial susceptibility of clinical Campylobacter jejuni and the molecular mechanisms of erythromycin-resistant isolates in Beijing, China[J]. Int J Infect Dis, 2016, 42(C):28-33. [24] Payot S, Bolla J M, Corcoran D, et al. Mechanisms of fluoroquinolone and macrolide resistance in Campylobacter spp[J]. Microbes Infect, 2006, 8(7):1967-1971. [25] Luo N, Sahin O, Lin J, et al. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump[J]. Antimicrob Agents Chemother, 2003, 47(1):390-394. [26] Luo N, Pereira S, Sahin O, et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure[J]. Proc Natl Acad Sci U S A, 2005, 102(3):541-546. [27] Wang L, Zhang YS, Zhang YH, et al. Mutant prevention concentrations of fluoroquinolones against Campylobacter jejuni isolated from chicken[J]. Vet Microbiol, 2010, 144(3-4):409-414. [28] Chen X, Wang Y, Luo PJ, et al. Characterization of quinolone resistance mechanisms among Campylobacter jejuni of broilers originated from Shandong province[J]. Chin J Vet Medicine,2013, 49(6):69-70.(in Chinese) 陈霞, 汪洋, 骆鹏杰,等. 山东省鸡源空肠弯曲菌喹诺酮类药物耐药机制研究[J].中国兽医杂志, 2013, 49(6):69-70. [29] Zhang T, Cheng Y, Luo Q, et al. The correlation between gyrA and CmeR-Box polymorphism and fluoroquinolones resistance in Campylobacter jejuni isolates in China.[J]. Antimicro Agents Chemother, 2017, 61(7):00422-00417. [30] Hu XJ, Han XF, Zhu DM, et al. Molecular characteristics of multidrug resistant Campylobacter jejuni and Campylobacter coli isolated from broilers[J]. Chin J Zoonoses, 2015, 31(8):694-699. doi:10.3969/cjz.j.issn 1002-2694.2015.08.002 (in Chinese) 胡欣洁, 韩新锋, 朱冬梅,等. 肉鸡源多重耐药空肠、结肠弯曲菌的耐药分子特征[J]. 中国人兽共患病学报, 2015, 31(8):694-699.
2018, Vol. 34 
